Targeting HMGB1: An available Therapeutic Strategy for Breast Cancer Therapy

被引:41
作者
Dong, Haonan
Zhang, Lu
Liu, Suling
机构
[1] Fudan Univ, Shanghai Canc, Shanghai 200032, Peoples R China
[2] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China
[3] Fudan Univ, Inst Canc, Shanghai 200032, Peoples R China
[4] Fudan Univ, Key Lab Breast Canc Shanghai, Shanghai 200032, Peoples R China
[5] Fudan Univ, Shanghai Key Lab Med Epigenet, Shanghai 200032, Peoples R China
[6] Fudan Univ, Shanghai Key Lab Radiat Oncol, Shanghai 200032, Peoples R China
[7] Fudan Univ, Int Colaboratory Med Epigenet & Metab, Minist Sci & Technol, Shanghai 200032, Peoples R China
[8] Fudan Univ, Shanghai Med Coll, Shanghai 200032, Peoples R China
来源
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES | 2022年 / 18卷 / 08期
基金
中国国家自然科学基金;
关键词
HMGB1; breast cancer; autophagy; immunogenic cell death; therapy; MOBILITY GROUP BOX; IMMUNOGENIC CELL-DEATH; ANTICANCER CHEMOTHERAPY; INFLAMMATORY RESPONSES; TUMOR-SUPPRESSOR; DOWN-REGULATION; ACIDIC TAIL; STEM-CELLS; AUTOPHAGY; DNA;
D O I
10.7150/ijbs.73504
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
HMGB1 is a member of highly conserved high mobility group protein superfamily with intracellular and extracellular distribution. Abnormal HMGB1 levels are frequently manifested in various malignant diseases, including breast cancer. Numerous studies have revealed the clinical value of HMGB1 in the diagnosis and therapy of breast cancer. However, the dual function of pro- and anti-tumor makes HMGB1 in cancer progression requires more profound understanding. This review summarizes the functions and mechanisms of HMGB1 on regulating breast cancer, including autophagy, immunogenic cell death, and interaction with the tumor microenvironment. These functions determine the strategies for the development of chemotherapy, radiotherapy, immunotherapy and combination therapies by targeting HMGB1 in breast cancer. Defining the mechanisms of HMGB1 on regulating breast cancer development and progression will facilitate the application of HMGB1 as a therapeutic target for breast cancer.
引用
收藏
页码:3421 / 3434
页数:14
相关论文
共 154 条
[1]   Targeting immunogenic cell death in cancer [J].
Ahmed, Asma ;
Tait, Stephen W. G. .
MOLECULAR ONCOLOGY, 2020, 14 (12) :2994-3006
[2]   microRNAs-107 inhibited autophagy, proliferation, and migration of breast cancer cells by targeting HMGB1 [J].
Ai, Hongyan ;
Zhou, Wei ;
Wang, Zeqiang ;
Qiong, Guo ;
Chen, Zhouxi ;
Deng, Shungang .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (05) :8696-8705
[3]   Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells [J].
Amornsupak, Kamolporn ;
Insawang, Tonkla ;
Thuwajit, Peti ;
O-Charoenrat, Pornchai ;
Eccles, Suzanne A. ;
Thuwajit, Chanitra .
BMC CANCER, 2014, 14
[4]   Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers [J].
Ananthula, Suryatheja ;
Sinha, Abhilasha ;
El Gassim, Mohamed ;
Batth, Simran ;
Marshall, Gailen D., Jr. ;
Gardner, Lauren H. ;
Shimizu, Yoshiko ;
El Shamy, Wael M. .
ONCOTARGET, 2016, 7 (15) :20869-20889
[5]   Nucleosome Structure(s) and Stability: Variations on a Theme [J].
Andrews, Andrew J. ;
Luger, Karolin .
ANNUAL REVIEW OF BIOPHYSICS, VOL 40, 2011, 40 :99-117
[6]  
[Anonymous], Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial) - Full Text View - ClinicalTrials.gov
[7]  
[Anonymous], SAFETY EFFICACY EVAL
[8]   Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma [J].
Aoto, Keita ;
Mimura, Kousaku ;
Okayama, Hirokazu ;
Saito, Motonobu ;
Chida, Shun ;
Noda, Masaru ;
Nakajima, Takahiro ;
Saito, Katsuharu ;
Abe, Noriko ;
Ohki, Shinji ;
Ohtake, Tohru ;
Takenoshita, Seiichi ;
Kono, Koji .
ONCOLOGY REPORTS, 2018, 39 (01) :151-159
[9]   The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy [J].
Apetoh, Lionel ;
Ghiringhelli, Francois ;
Tesniere, Antoine ;
Criollo, Alfredo ;
Ortiz, Carla ;
Lidereau, Rosette ;
Mariette, Christophe ;
Chaput, Nathalie ;
Mira, Jean-Paul ;
Delaloge, Suzette ;
Andre, Fabrice ;
Tursz, Thomas ;
Kroemer, Guido ;
Zitvogel, Laurence .
IMMUNOLOGICAL REVIEWS, 2007, 220 :47-59
[10]   Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].
Apetoh, Lionel ;
Ghiringhelli, Francois ;
Tesniere, Antoine ;
Obeid, Michel ;
Ortiz, Carla ;
Criollo, Alfredo ;
Mignot, Gregoire ;
Maiuri, M. Chiara ;
Ullrich, Evelyn ;
Saulnier, Patrick ;
Yang, Huan ;
Amigorena, Sebastian ;
Ryffel, Bernard ;
Barrat, Franck J. ;
Saftig, Paul ;
Levi, Francis ;
Lidereau, Rosette ;
Nogues, Catherine ;
Mira, Jean-Paul ;
Chompret, Agnes ;
Joulin, Virginie ;
Clavel-Chapelon, Francoise ;
Bourhis, Jean ;
Andre, Fabrice ;
Delaloge, Suzette ;
Tursz, Thomas ;
Kroemer, Guido ;
Zitvogel, Laurence .
NATURE MEDICINE, 2007, 13 (09) :1050-1059